Science & academia

This archive covers milestones and breakthroughs from the scientific and academic world — researchers, universities, and institutions whose work advances human knowledge. Stories here highlight discoveries, studies, and scholarly efforts that point toward a better future.

Hands making hear shape over transgender flag in background

More than 90% of trans people are more satisfied with life after transitioning, massive new study finds

By / / Good news links

Ninety-four percent of transgender people said that they were either a little or a lot more satisfied with their lives since they transitioned, the 2022 U.S. Transgender Survey (USTS) by the National Center for Transgender Equality (NCTE) found. The study, which is the latest edition of the influential survey of transgender people, involved 92,329 transgender and nonbinary respondents answering questions about various aspects of their lives from October 19 to December 5, 2022.

Assortment of pills

Novel AI model rapidly determines if an antidepressant will work

By / / Good news links

Amsterdam University Medical Center (UMC) and Radboud UMC researchers have developed an algorithm that, based on patient MRI scans and other data, can determine within a week if a particular antidepressant will, offering faster relief and minimizing often painful and damaging side effects. “This is important news for patients,” said Liesbeth Reneman, Professor of Neuroradiology at Amsterdam UMC. “Normally, it takes six to eight weeks before it is known whether an antidepressant will work.”

Chromosomes, for article on CRISPR gene therapy hereditary angioedema

Gene therapy hailed as ‘medical magic wand’ for hereditary swelling disorder

By / / Good News For Humankind

CRISPR gene editing has freed ten patients with hereditary angioedema from the sudden, sometimes life-threatening swelling attacks that shaped their daily lives, with several remaining attack-free for 18 months and counting after a single infusion. The therapy works by switching off a gene in liver cells, stopping the painful chain reaction at its source rather than just managing symptoms. One participant who used to have attacks every three weeks has needed no medication since. Doctors are now recruiting for a phase-three trial, building on the same Nobel-winning technology that recently produced an approved cure for sickle cell disease. For a rare condition long defined by unpredictability and fear, it’s a glimpse of what gene editing could mean for millions living with inherited illness worldwide.

Person having blood drawn, for article on Alzheimer's blood test

Breakthrough Alzheimer’s blood test could detect disease 15 years before symptoms emerge

By / / Good News For Humankind

A simple Alzheimer’s blood test trialed in Sweden can detect the disease’s biological signs up to 15 years before symptoms appear, matching the accuracy of a spinal tap in a study of 786 people. The test measures p-tau217, a protein that builds up in the blood as Alzheimer’s-related changes unfold in the brain. Researchers suggest it could one day be as routine as a cholesterol check for anyone over 50, replacing painful lumbar punctures and hard-to-access specialist scans. With one in three people born in the U.K. today expected to develop dementia, catching the disease early — while there’s still time to intervene — could transform how the world confronts one of its most feared illnesses.

Person receiving shot in the arm, for article on melanoma cancer vaccine

Cancer vaccine with minimal side effects nearing Phase 3 clinical trials

By / / Good News For Humankind

A personalized cancer vaccine is heading into Phase 3 trials after a remarkable Phase 2 result: nearly 95% of advanced melanoma patients who received only the vaccine were still alive three years later. What makes Dr. Thomas Wagner’s TLPO vaccine so striking isn’t just the survival numbers — it’s the gentleness. Patients report little more than a sore arm and mild fatigue, a world away from the dread of chemotherapy. The vaccine is made from each patient’s own tumor cells, teaching their immune system to recognize cancer as the threat it is. If the larger trial holds up, it could reshape how we think about treating cancer everywhere — not as something to endure, but something to outsmart.

Artist's concept of a solar power satellite in place, for article on space solar power

First ever space-to-Earth solar power mission succeeds

By / / Good News For Humankind

Space-based solar power just cleared a milestone scientists have been chasing since the 1970s: a Caltech satellite spent a year in orbit, collected sunlight, and beamed it wirelessly back to a ground receiver on Earth. The SSPD-1 mission completed all three of its planned experiments, including testing an origami-inspired panel that unfolds without hinges and a purpose-built microwave transmitter. The appeal is simple — above the atmosphere, the Sun never sets, no clouds get in the way, and power could flow around the clock. Caltech’s team is honest that commercial-scale space solar is still years off, with cost and radiation durability to solve. But moving this idea from whiteboard to working demonstration brings humanity a real step closer to truly continuous clean energy.

A family grocery shopping together for an article about consumption poverty in the U.S.

U.S. consumption poverty has fallen 27 percentage points since 1980

By / / Good News For Humankind

Consumption poverty in the United States has fallen dramatically since 1980, according to a major new study from the University of Notre Dame. Researchers found the poverty rate dropped 27 percentage points when measured by what families actually spend rather than what they report earning. The official income-based measure, by contrast, showed only a 1.5 percentage point decline over the same period. The findings suggest decades of policy investment in Social Security, tax credits, and safety net programs have produced far greater results than conventional statistics indicate.

Person receiving nasal spray, for article on intranasal COVID-19 vaccine

Novel nasal COVID-19 vaccine offers longer, better immunity than jabs

By / / Good News For Humankind

A nasal COVID-19 vaccine developed at Duke-NUS Medical School in Singapore is showing real promise: in hamster studies, it produced more central memory T cells than standard injections, hinting at protection that could last considerably longer. By delivering the vaccine right where the virus enters the body, researchers also saw stronger antibody responses against newly emerging variants. The team has filed a patent that covers other respiratory pathogens too, opening doors for future flu and RSV vaccines. Human trials are still ahead, but for anyone weary of frequent boosters — especially elderly and immunocompromised people — a needle-free shot offering broader, longer protection could meaningfully reshape how the world lives alongside evolving respiratory viruses.

Cancer cells, for article on multi-cancer blood test

New protein test can detect 18 early stage cancers, scientists say

By / / Good News For Humankind

A new blood test can screen for 18 different cancers at once — covering every major organ in the body — using a single ordinary blood draw. Researchers at U.S. biotech firm Novelna found the test caught 93% of earliest-stage cancers in male samples and 84% in female samples, while also pinpointing which organ the cancer came from in more than 80% of cases. Instead of hunting for tumor DNA, the team analyzed proteins in blood plasma, picking up faint signals before a tumor does visible damage. Larger studies are still needed before it reaches clinics, but a cheap, accurate, broad screening tool would be a quiet revolution for global health — especially in places where late diagnosis is still the norm.